Introduction: Anticoagulation without bleeding is an ideal goal in treating thrombosis,
however, this goal has not been achieved. All current anticoagulants are associated with …

Despite advances in anticoagulant therapy, thrombosis remains the leading cause of
morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first …

Highlights•Factor XI is the precursor of a plasma protease (factor XIa) that contributes to
normal blood coagulation (hemostasis).•Factor XIa contributes to thrombosis in humans.•In …

Parenteral and oral factor XI (FXI) inhibitors, the next potential generation of anticoagulants,
are undergoing phase-3 evaluation with the hope that they will be safer than currently …

The evolution of anticoagulation therapy, from vitamin K antagonists to the advent of direct
oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite …

Factor XI is almost dispensable for haemostasis, but its role in thrombosis has become
increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no …

Arterial and venous thromboembolism is a major medical concern that requires therapeutic
anticoagulation in various medical fields to prevent its drastic consequences. Despite …

Background Phase II randomized controlled trials (RCTs) on factor (F) XI inhibitors have
shown promising results but they were burdened by low statistical power for clinical …

Abstract Factor XIa (FXIa) is a serine protease homodimer that belongs to the intrinsic
coagulation pathway. FXIa primarily catalyzes factor IX activation to factor IXa, which …

Prevention and treatment of thromboembolic disorders with minimal bleeding risk remains a
significant unmet medical need. Studies in Factor XI (FXI)-deficient humans and …